NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
Clinical Trials
24 trialsNCT05283720 2026-04-13
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT05798156 2026-04-08
R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT06890884 2026-04-02
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT05800366 2026-03-05
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07397832 2026-02-09
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06594939 2026-02-04
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
NCT06803693 2025-12-08
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
Phase 2 Recruiting
NCT06765317 2025-11-26
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04479267 2025-09-29
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Active not recruiting
NCT04665765 2025-09-03
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06664411 2025-08-19
Pola-ZR2P in Previously Untreated DLBCL
Navy General Hospital, Beijing
Phase 2 Recruiting
NCT06665217 2025-08-14
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT07012980 2025-06-10
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06530511 2025-02-04
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT06554600 2024-08-15
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06516978 2024-07-24
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06441097 2024-06-04
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06176729 2023-12-20
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05940051 2023-07-11
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05940064 2023-07-11
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04535102 2022-05-09
POLA+BR for Relapsed or Refractory DLBCL
University of Colorado, Denver
Phase 2 Withdrawn